The US and Canada have healthcare, life science and medical device industries that are complex and interconnected.
On March 6, President Donald Trump instituted a 25 percent ad valorem rate of duty on goods imported from Canada under the International Emergency Economic Powers Act.[1] The tariffs will not be implemented on goods that comply with the United States-MexicoCanada Agreement until April 2.[2] In turn, Canada has announced a $155 billion tariff package on the US.[3]
Download the full Law360 article, "Mitigating Tariff Risks For Healthcare In US And Canada."
Publication
Our 23rd report spotlights landmark legislative reforms such as the UK’s new Arbitration Act 2025 and South Africa’s rise as a regional arbitration hub. We examine procedural innovations, enforcement challenges, and the evolving role of tribunals in promoting settlement.
Publication
Artificial intelligence (AI) is transforming established practices in multiple areas across all industries, and mergers and acquisitions (M&A) are not immune to this transformation.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2025
